Results 211 to 220 of about 4,422,072 (371)
Abstract Defining the CSF cytokine/chemokine and injury biomarker signature of glial fibrillary acidic protein (GFAP) autoimmunity can inform immunopathogenesis. CSF GFAP‐IgG‐positive samples (N = 98) were tested for 17 cytokines/chemokines, neurofilament light chain (NfL), and GFAP (ELLA, Bio‐Techne).
Yahel Segal+11 more
wiley +1 more source
Luteolin: a natural product with multiple mechanisms for atherosclerosis. [PDF]
Wan C+7 more
europepmc +1 more source
Recent advances in the chemistry of natural products [PDF]
R. B. Woodward
openalex +1 more source
Subthalamic Nucleus Oscillatory Characteristics in Meige, Cervical Dystonia and Generalized Dystonia
ABSTRACT Objective Deep brain stimulation offers a unique opportunity to record neural activity of the basal ganglia. While much work in dystonia has focused on the globus pallidus internus, expanding research to investigate subthalamic nucleus (STN) activity in various dystonia types is critical to provide a comprehensive understanding of dystonia ...
Zhu Guan‐Yu+14 more
wiley +1 more source
Natural Product Synthesis Enabled by Radical-Polar Crossover Reactions. [PDF]
Müller N, Magauer T, Kováč O.
europepmc +1 more source
ABSTRACT Background and Objectives Ofatumumab, a fully human anti‐CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing–remitting multiple ...
Shu Yang+9 more
wiley +1 more source
Semiempirical rules in circular dichroism of natural products [PDF]
G. Snatzke
openalex +1 more source
Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study
ABSTRACT Objective Identifying functional measures that are both valid and reliable in the limb girdle muscular dystrophy (LGMD) population is critical for quantifying the level of functional impairment related to disease progression in order to establish clinical trial readiness in the context of anticipated therapeutic trials.
Stephanie M. Hunn+29 more
wiley +1 more source